<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="234">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405102</url>
  </required_header>
  <id_info>
    <org_study_id>2021-3474</org_study_id>
    <nct_id>NCT04405102</nct_id>
  </id_info>
  <brief_title>COVID-19 Ozanimod Intervention Study</brief_title>
  <acronym>COZI</acronym>
  <official_title>A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The virus SARS-CoV-2 causes severe pneumonia which, in a proportion of patients progresses
      towards an Acute Respiratory Distress Syndrome (ARDS) mainly related to the antiviral immune
      response. To date, there is no available treatment that significantly improves outcome of
      patients with COVID-19 pneumonia. Sphingosine-1-phosphate receptor 1 (S1P1) ligands control
      vascular leakage in the airways and sphingosine-1-phosphate (S1P) receptor ligands devoid of
      activity on sphingosine-1-phosphate receptor 3 (S1P3) show an excellent safety profile,
      including ozanimod. Critically, S1P1 ligands mildly impact, but do not compromise viral
      clearance and they reduced lung injury in the highly pathogenic H1N1-ferret model, even
      without concomitant use of antivirals and with a synergistic effect when associated to
      antiviral agents. Ozanimod was approved by the FDA for the treatment of relapsing multiple
      sclerosis at the end of March 2020. The investigators believe that this immune modulator is
      at the top of the list of agents that should be trialed in order to mitigate the morbidity
      and mortality of COVID-19.

      The primary objective is to substantiate the impact of ozanimod on key outcomes of COVID-19
      patient progression, which will guide decision making around sample size and the choice of
      endpoints for future clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale</measure>
    <time_frame>through whole duration of the hospitalization, an average of 14 days</time_frame>
    <description>Clinical improvement until hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean oxygen flow required to maintain the oxygen saturation (SpO2) target at 92%</measure>
    <time_frame>First 7 days of the trial</time_frame>
    <description>Titrated every second with automated oxygen titration device (FreeO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non invasive ventilation (NIV) / high flow nasal therapy (HFNT) use</measure>
    <time_frame>through whole duration of the hospitalization, an average of 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intubation</measure>
    <time_frame>through whole duration of the hospitalization, an average of 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days at day 28</measure>
    <time_frame>through whole duration of the hospitalization, an average of 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ICU admission/length of stay/mortality</measure>
    <time_frame>through whole duration of the hospitalization, an average of 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity index measurement</measure>
    <time_frame>through whole duration of the hospitalization, an average of 14 days</time_frame>
    <description>Sepsis-related organ failure assessment (SOFA), national early warning score (NEWS2), early warning score for oxygen therapy (EWS.O2), decrease of at least 2 points on the 6-point ordinal scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Ozanimod + standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During hospitalization, the experiment treatment of Ozanimod will be given with the standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data.).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozanimod</intervention_name>
    <description>The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.</description>
    <arm_group_label>Ozanimod + standard of care</arm_group_label>
    <other_name>Zeposia (USA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).</description>
    <arm_group_label>Ozanimod + standard of care</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Confirmed COVID-19 (positive polymerase chain reaction (PCR) for COVID-19 from any
             specimen)

          -  Patients older than 18 years old and younger than 85 years old.

          -  BMI higher than 20 but lower than 35

          -  Patients with hypoxemia related to viral pneumonia (COVID-19) requiring oxygen therapy
             below 6 L/min (or fraction of inspired oxygen (FiO2) &lt; 0.50) (to maintain SpO2 above
             92%) without criteria for immediate intubation or need for other respiratory supports
             (CPAP, non-invasive ventilation of high flow nasal therapy).

          -  Patients hospital admission &lt; 72 hours

          -  Serum creatinine &lt; 124 μmol/L

          -  Serum troponin &lt; 28 ng/L

        Exclusion criteria Medical conditions

          -  Level of care B, C or D (patient admitted for palliative care; or physician is not
             committed to life-sustaining therapies)

          -  No SpO2 signal available

          -  Patient agitation

          -  Severe sleep apnea

          -  History of or currently active primary or secondary immunodeficiency

          -  Recent (within the last 6 months) occurrence of myocardial infarction, unstable
             angina, stroke, transient ischemic attack, decompensated heart failure requiring
             hospitalization, class III/IV heart failure

          -  Known presence of Mobitz type II second-degree or third-degree atrioventricular block,
             sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker

          -  Child-Pugh score class C

          -  Pregnancy, lactation, or a positive serum beta human chorionic gonadotropin measured
             during screening.

        Prior/concomitant therapy

          -  Receipt of a live vaccine within 4 weeks prior to randomization

          -  Receiving MAO inhibitor (tranylcypromine, selegiline or phenelzine)

          -  Receiving pharmacological treatment for a form of multiple sclerosis

          -  Use of long-term immunosuppressors (Ex. tacrolimus, cyclosporin, azathioprine,
             mycophenolate, sirolimus, methotrexate; and chronic use of corticosteroid (&gt; 7.5 mg
             per day more than 3 months)

          -  Receiving Class 1a and class III anti-arrythmic drugs amiodarone, sotalol, flecainide,
             propafenone

          -  Patients receiving or anticipated to receive chloroquine or azithromycin.

        Prior/concurrent clinical study experience -Current enrolment in a clinical trial with
        similar endpoints to the COZI trial

        Other exclusions

        -Patients or legal/authorized representatives who refuse to participate to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Lellouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IUCPQ-UL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Marsolais, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CRIUCPQ-UL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie Châteauvert, B. pharm</last_name>
    <role>Study Chair</role>
    <affiliation>CRIUCPQ-UL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascale Blais-Lecours, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CRIUCPQ-UL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascale Blais-Lecours, PhD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>2651</phone_ext>
    <email>pascale.blais-lecours@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Marsolais, PhD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3085</phone_ext>
    <email>david.marsolais@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lizotte</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3937</phone_ext>
      <email>patricia.lizotte@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>François Lellouche, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Marsolais, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Châteauvert, B.Sc, B. pharm, M.Sc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>François Lellouche</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>S1P1 ligand</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Oxygen requirement</keyword>
  <keyword>WHO-adapted 6-points ordinal scale</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

